Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Collins

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Leukemia|September 19, 2024
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacyAndrew J Innes, Chloe Hayden, Victoria Orovboni, et al.
Blood Advances|September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapyJad Othman, Angela Hwang, Maximillian Brodermann, et al.
Blood Neoplasia|June 2, 2025
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
Leukemia|March 13, 2025
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia veraYan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw, et al.
Blood Advances|July 8, 2022
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needsMarta Sobas, Jean-Jacques Kiladjian, Yan Beauverd, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Leukemia|September 19, 2024
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacyAndrew J Innes, Chloe Hayden, Victoria Orovboni, et al.
Blood Advances|September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapyJad Othman, Angela Hwang, Maximillian Brodermann, et al.
Blood Neoplasia|June 2, 2025
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
Leukemia|March 13, 2025
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia veraYan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw, et al.
Blood Advances|July 8, 2022
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needsMarta Sobas, Jean-Jacques Kiladjian, Yan Beauverd, et al.
Pageof 4